study_id,author_year,title,study_design,ending_year,world_region,world_subregion,country,city_state,focus,overall_cytology,pap_method,recruitment_setting,hpv_types_reported,hpv_test,num_older_wom,num_hpv_pos,num_hr_hpv_pos,hpv_type,num_type,type_prev,notes
4HG,"Yoshida et al., 2007","Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions",cross-sectional ,2004,Asia,Eastern Asia,Japan,Gunma,Both ,Predominantly normal ,LBC,clinical setting ,"HR-HPV, 16",PCR E6/E7,148,NA,30,16,3.6,0.024324324,"numbers are not reported in table format but as figures therefore there is a visual extrapolation done for % positivity, and data only separated for 55+ and 65+, because 50 is lost in the cat of 45-54"
2OG,"Çolakoğlu et al., 2017",Human papilloma virus (HPV) prevalence and genotype distribution,cross-sectional ,2015,Asia,Western Asia,Turkey,Adana,Both ,Predominantly normal ,LBC,screening,"16, 18 overall",LA,52,23,NA,"16,18",7,0.134615385,Table 2 
4OG,"Dutta et al, 2012","Prevalence of Human Papillomavirus in Women Without
Cervical Cancer: A Population-based Study in Eastern India",cross-sectional ,2010,Asia,Southern Asia,India,West Bengal,Both ,Predominantly normal ,Conventional ,screening,"16, 18, overall ",MY09/11,114,11,NA,16,1,0.00877193,Table 4
4OG,"Dutta et al, 2012","Prevalence of Human Papillomavirus in Women Without
Cervical Cancer: A Population-based Study in Eastern India",cross-sectional ,2010,Asia,Southern Asia,India,West Bengal,Both ,Predominantly normal ,Conventional ,screening,"16, 18, overall",MY09/11,114,11,NA,18,1,0.00877193,Table 4
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,16,12,0.011417697,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,screening,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,"18,45",5,0.004757374,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,31,6,0.005708849,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,"33, 52, 58",9,0.008563273,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,35,3,0.002854424,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,39,4,0.003805899,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,51,4,0.003805899,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,56,3,0.002854424,Fig 3
8HG,"Hermansson et al., 2018",HPV prevalence and HPV-related dysplasia in elderly women,retrospective,2015,Europe,Northern Europe,Sweden,Mora,Older,Predominantly normal ,LBC,clinical setting ,"16, 18/45, 31, 33/52/58, 35, 39, 51, 56, 59",other PCR,1051,NA,43,59,2,0.00190295,Fig 3
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,16,113,0.061048082,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,18,31,0.016747704,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,31,31,0.016747704,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,33,46,0.024851432,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,35,24,0.012965964,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,39,27,0.01458671,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,45,10,0.005402485,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,51,60,0.032414911,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,52,149,0.080497029,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,56,71,0.038357645,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,58,83,0.044840627,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,59,45,0.024311183,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,66,61,0.032955159,Table 2 
6OHG,"Jin et al., 2019","The prevalence and genotype distribution of
human papillomaviruses among women in
Taizhou, China",retrospective,2018,Asia ,Eastern Asia,China ,Taizhou,Both ,Predominantly normal ,NA,clinical setting ,"16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68",other PCR,1851,745,650,68,61,0.032955159,Table 2 
10OHG,"Richter et al., 2013","Age-specific prevalence of cervical human
papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa",cross-sectional ,2011,Africa,Southern Africa,South Africa,Gauteng,Both ,Predominantly normal ,conventional ,screening,"16, 18, 16/18",LA,325,137,82,16,19,0.058461538,Table 1
10OHG,"Richter et al., 2013","Age-specific prevalence of cervical human
papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa",cross-sectional ,2011,Africa,Southern Africa,South Africa,Gauteng,Both ,Predominantly normal ,conventional ,screening,"16, 18, 16/18",LA,325,137,82,18,14,0.043076923,Table 1
10OHG,"Richter et al., 2013","Age-specific prevalence of cervical human
papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa",cross-sectional ,2011,Africa,Southern Africa,South Africa,Gauteng,Both ,Predominantly normal ,conventional ,screening,"16, 18, 16/18",LA,325,137,82,"16,18",33,0.101538462,Table 1
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,16,96,0.013237728,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,18,30,0.00413679,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",mulitple,7252,NA,503,31,50,0.00689465,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,45,24,0.003309432,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",mulitple,7252,NA,503,"33,58",54,0.007446222,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,"35,39,68",139,0.019167126,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,51,21,0.002895753,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,52,80,0.01103144,Table 3
71HG,"Stoler et al., 2018","The Onclarity Human Papillomavirus Trial: Design, methods, and
baseline results",prospective,2018,Americas ,North America,USA,NA,Both ,Predominantly normal ,LBC,screening ,"16, 18, 31, 45, 33/58, 35/39/68, 51, 52, 56/59/66",multiple,7252,NA,503,"56,59,66",125,0.017236624,Table 3
17HG,"Wu et al., 2017","A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women",prospective,2015,Asia,Eastern Asia,China,Longyou County,Both ,Predominantly normal ,LBC,general population,"HR-HPV, 16/18",Cobas,3859,NA,447,"16,18",109,0.028245659,Figure 3
16OHG,"Brotherton et al., 2015",Human papillomavirus prevalence to age 60 years among Australian women prevaccination,cross-sectional ,2008,Oceania,Austraiia and New Zealand,Australia,NA,Both ,Predominantly normal ,LBC,clinical setting ,"HR-HPV, 6/11/16/18, 16/18",PGMY09/11,135,23,12,6/11/16/18,5,0.037037037,Table 1
16OHG,"Brotherton et al., 2015",Human papillomavirus prevalence to age 60 years among Australian women prevaccination,cross-sectional ,2008,Oceania,Austraiia and New Zealand,Australia,NA,Both ,Predominantly normal ,LBC,clinical setting ,"HR-HPV, 6/11/16/18, 16/18",PGMY09/11,135,23,12,16/18,5,0.037037037,Table1
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,16,26.603,0.018246228,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,18,8.788,0.006027435,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,31,8.466,0.005806584,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,33,4.568,0.003133059,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,35,7.889,0.005410837,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,39,4.233,0.002903292,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,45,2.864,0.001964335,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,51,6.833,0.004686557,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,52,7.152,0.00490535,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,56,15.759,0.010808642,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,58,8.147,0.005587791,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,59,4.248,0.00291358,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
24HG,"Agarossi et al., 2009","Prevalence and Type Distribution of High-Risk
Human Papillomavirus Infection in Women
Undergoing Voluntary Cervical Cancer
Screening in Italy",cross-sectional ,2006,Europe,Southern Europe,Italy,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68",GP5+/GP6+,1458,NA,104,68,8.288,0.005684499,need to calculate N of infected by type individually based on % from table 1 by age group and then sum up
25HG,"Agorastos et al., 2019",Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study,cross-sectional ,2018,Europe,Southern Europe,Greece,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18 ",Cobas,4788,NA,238,16,32,0.006683375,Table 4
25HG,"Agorastos et al., 2019",Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study,cross-sectional ,2018,Europe,Southern Europe,Greece,NA,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18 ",Cobas,4788,NA,238,18,18,0.003759398,Table 4
18OHG,"Andujar et al., 2020","Prevalence and genotype distribution of
cervical human papilomavirus infection
in the pre-vaccination
era: a population-based
study in the Canary Islands",cross-sectional ,2007,Europe,Southern Europe,Spain,Canary Islands,Both ,Predominantly normal ,conventional ,screening,"HR-HPV, 16/18, 6/11/16/18/31/33/45/52/58",MY09/11 and GP5+/GP6+,1601,129,85.91,16/18,21.725,0.013569644,Figure 1 using PlotDigitizer
18OHG,"Andujar et al., 2020","Prevalence and genotype distribution of
cervical human papilomavirus infection
in the pre-vaccination
era: a population-based
study in the Canary Islands",cross-sectional ,2007,Europe,Southern Europe,Spain,Canary Islands,Both ,Predominantly normal ,conventional ,screening,"HR-HPV, 16/18, 6/11/16/18/31/33/45/52/58",MY09/11 and GP5+/GP6+,1601,129,85.91,6/11/16/18/31/33/45/52/58,44.05,0.027514054,Figure 1 using PlotDigitizer
29HG,"Bergengren et al., 2020","Prevalence of HPV and pathological changes among women 70 years
of age, 10 years after exclusion from the Swedish cervical cancer
screening program",cross-sectional ,2017,Europe,Northern Europe,Sweden,Örebro County,Older,Predominantly normal ,LBC,general population,"HR-HPV, 16, 33, 68",PCR E6/E7,809,NA,31,16,4.854,0.006,0.006 prevalence for type 16
29HG,"Bergengren et al., 2020","Prevalence of HPV and pathological changes among women 70 years
of age, 10 years after exclusion from the Swedish cervical cancer
screening program",cross-sectional ,2017,Europe,Northern Europe,Sweden,Örebro County,Older,Predominantly normal ,LBC,general population,"HR-HPV, 16, 33, 68",PCR E6/E7,809,NA,31,33,4.854,0.006,0.006 prevalence for type 33
29HG,"Bergengren et al., 2020","Prevalence of HPV and pathological changes among women 70 years
of age, 10 years after exclusion from the Swedish cervical cancer
screening program",cross-sectional ,2017,Europe,Northern Europe,Sweden,Örebro County,Older,Predominantly normal ,LBC,general population,"HR-HPV, 16, 33, 68",PCR E6/E7,809,NA,31,68,4.854,0.006,0.006 prevalence for type 68
30HG,"Bhar et al., 2015",Human papillomavirus (HPV) types 16 and 18 in liquid-based cervical cytology samples,prospective,NA,Asia,Southern Asia,India,Chandigarh,Both ,Predominantly normal ,LBC,screening,"16, 18, 16/18",other PCR,29,NA,16,16,12,0.413793103,Table 2
30HG,"Bhar et al., 2015",Human papillomavirus (HPV) types 16 and 18 in liquid-based cervical cytology samples,prospective,NA,Asia,Southern Asia,India,Chandigarh,Both ,Predominantly normal ,LBC,screening,"16, 18, 16/18",other PCR,29,NA,16,18,8,0.275862069,Table 2
30HG,"Bhar et al., 2015",Human papillomavirus (HPV) types 16 and 18 in liquid-based cervical cytology samples,prospective,NA,Asia,Southern Asia,India,Chandigarh,Both ,Predominantly normal ,LBC,screening,"16, 18, 16/18",other PCR,29,NA,16,16/18,4,0.137931034,Table 2
30OG,"Cathro et al., 2009","Human papillomavirus profile of women in Belize City, Belize: correlation with cervical cytopathologic findings",cross-sectional ,2007,Americas,Central America,Belize,Belize City,Both ,Predominantly normal ,conventional ,screening,"overall, 16, 18",GP5+/6+,44,3,NA,16,0,0,Figure 1 using PlotDigitizer
30OG,"Cathro et al., 2009","Human papillomavirus profile of women in Belize City, Belize: correlation with cervical cytopathologic findings",cross-sectional ,2007,Americas,Central America,Belize,Belize City,Both ,Predominantly normal ,conventional ,screening,"overall, 16, 18",GP5+/6+,44,3,NA,18,1.015,0.023068182,Figure 1 using PlotDigitizer
31OG,"Centurioni et al., 2005",Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population,cross-sectional ,1993,Europe,Southern,Italy,Genova,Both,Predominantly normal ,LBC,screening ,"overall, 6/11, 16, 18, 33",MY09/11,264,41,NA,"6,11",1,0.003787879,Table 2 
31OG,"Centurioni et al., 2005",Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population,cross-sectional ,1993,Europe,Southern,Italy,Genova,Both,Predominantly normal ,LBC,screening ,"overall, 6/11, 16, 18, 33",MY09/11,264,41,NA,16,28,0.106060606,Table 2 
31OG,"Centurioni et al., 2005",Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population,cross-sectional ,1993,Europe,Southern,Italy,Genova,Both,Predominantly normal ,LBC,screening ,"overall, 6/11, 16, 18, 33",MY09/11,264,41,NA,18,14,0.053030303,Table 2 
31OG,"Centurioni et al., 2005",Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population,cross-sectional ,1993,Europe,Southern,Italy,Genova,Both,Predominantly normal ,LBC,screening ,"overall, 6/11, 16, 18, 33",MY09/11,264,41,NA,33,2,0.007575758,Table 2 
34OHG,"Chen et al., 2015","Prevalence and Genotype Distribution of Cervical Human Papillomavirus (HPV) Among Women in Urban Tianjin, China",cross-sectional ,2013,Asia,Eastern Asia,China,Tianjin,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 58, 66",MY09/11 and GP5+/GP6+,747,110,89,16,34.91,0.046733601,prevalence for specific HR-HPV type reported in Figure 3 and extracted with Plot digitizer
34OHG,"Chen et al., 2015","Prevalence and Genotype Distribution of Cervical Human Papillomavirus (HPV) Among Women in Urban Tianjin, China",cross-sectional ,2013,Asia,Eastern Asia,China,Tianjin,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 58, 66",MY09/11 and GP5+/GP6+,747,110,89,18,9.127,0.012218206,prevalence for specific HR-HPV type reported in Figure 3 and extracted with Plot digitizer
34OHG,"Chen et al., 2015","Prevalence and Genotype Distribution of Cervical Human Papillomavirus (HPV) Among Women in Urban Tianjin, China",cross-sectional ,2013,Asia,Eastern Asia,China,Tianjin,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 58, 66",MY09/11 and GP5+/GP6+,747,110,89,58,19.088,0.025552878,prevalence for specific HR-HPV type reported in Figure 3 and extracted with Plot digitizer
34OHG,"Chen et al., 2015","Prevalence and Genotype Distribution of Cervical Human Papillomavirus (HPV) Among Women in Urban Tianjin, China",cross-sectional ,2013,Asia,Eastern Asia,China,Tianjin,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 58, 66",MY09/11 and GP5+/GP6+,747,110,89,66,3.973,0.005318608,prevalence for specific HR-HPV type reported in Figure 3 and extracted with Plot digitizer
39OG,"Debrah et al., 2021","Prevalence of vaccine and non‑vaccine
human papillomavirus types among women
in Accra and Kumasi, Ghana: a cross‑sectional
study",cross-sectional ,2015,Africa,Western Africa,Ghana,"Accra, Kumasi",Both ,Predominantly normal ,Conventional ,clinical setting ,"overall, 16/18",PCR E6/E7,7,2,NA,"16,18",0,0,Supplementary Table S1
40OHG,"Demers et al., 2012","Distribution of human papillomavirus types, cervical cancer screening history, and risk factors for infection in Manitoba",cross-sectional ,2008,Americas,North America,Canada,Manitoba,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16/18",other PCR,213,20,8,"16,18",4,0.018779343,"
TABLE 2
Age distribution of women by infection status and HPV type."
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,52,6,0.065934066,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,16,2,0.021978022,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,68,6,0.065934066,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,31,4,0.043956044,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,58,3,0.032967033,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,18,3,0.032967033,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,56,3,0.032967033,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,51,1,0.010989011,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,39,3,0.032967033,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,45,1,0.010989011,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,35,1,0.010989011,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,33,1,0.010989011,Table 3 for age specific HPV Genotype specific data
41OHG,"Dufit et al., 2016","THE EPIDEMIOLOGY OF HUMAN PAPILLOMA VIRUS IN WOMEN AGED 20-65 YEARS LIVING IN REMOTE VILLAGES
IN FRENCH GUIANA: ADAPTING INTERVENTIONS TO THE TERRITORY",cross-sectional ,2014,Americas,South America,French Guiana,NA,Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV+, 52, 15, 68, 31, 58, 18, 56, 51, 39, 45, 35, 33, 59",other PCR,91,40,30,59,1,0.010989011,Table 3 for age specific HPV Genotype specific data
45OHG,"Foliaki et al., 2014",Prevalence of HPV infection and other risk factors in a Fijian population,cross-sectional ,2010,Oceania,Melanesia,Fiji,Suva,Both,Predominantly normal ,NA,general population,"overall, HR-HPV, 16/18",GP5+/6+,70,13,4,"16,18",1.8756,0.026794286,Figure 1 using PlotDigitizer
47OHG,"Hamlin-Douglas et al., 2008","Prevalence and Age Distribution of Human
Papillomavirus Infection in a Population
of Inuit Women in Nunavik, Quebec",prospective,2007,Americas,North America,Canada,"Nunavik, Quebec",Both,Predominantly normal ,Conventional ,screening ,"overall, HR-HPV, 16/18",PGMY09/11,121,24,11,"16,18",2.95,0.024380165,"HPV types 16 or 18 were detected in 2.2% in ages 50-59 y, and
3.1% in ages 60-69 y"
43HG,"He et al., 2019","Distribution of high-risk HPV types among
women in Sichuan province, China: a crosssectional
study",cross-sectional ,2016,Asia ,Eastern Asia,China ,Sichuan,Both,Predominantly normal ,LBC,screening,HR-HPV; 16/18; 31/45/52/58; 26/35/39/51/53/56/59/66/68/82,GP5+/GP6+,4808,NA,562,"16,18",91.7,0.019072379,Figure 2 for N breakdown by age group; Figure 1 total HR-HPV prevalence; Figure for specific genotype prevalence
43HG,"He et al., 2019","Distribution of high-risk HPV types among
women in Sichuan province, China: a crosssectional
study",cross-sectional ,2016,Asia ,Eastern Asia,China ,Sichuan,Both,Predominantly normal ,LBC,screening,HR-HPV; 16/18; 31/45/52/58; 26/35/39/51/53/56/59/66/68/82,GP5+/GP6+,4808,NA,562,31/45/52/58,266.3,0.055386855,Figure 2 for N breakdown by age group; Figure 1 total HR-HPV prevalence; Figure for specific genotype prevalence
43HG,"He et al., 2019","Distribution of high-risk HPV types among
women in Sichuan province, China: a crosssectional
study",cross-sectional ,2016,Asia ,Eastern Asia,China ,Sichuan,Both,Predominantly normal ,LBC,screening,HR-HPV; 16/18; 31/45/52/58; 26/35/39/51/53/56/59/66/68/82,GP5+/GP6+,4808,NA,562,26/35/39/51/53/56/59/66/68/82,340.04,0.070723794,Figure 2 for N breakdown by age group; Figure 1 total HR-HPV prevalence; Figure for specific genotype prevalence
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,16,43.229,0.026967561,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,18,23.237,0.014495945,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,26,4.001,0.002495945,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,31,18.415,0.011487835,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,33,13.606,0.008487835,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,35,8.784,0.005479726,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,39,6.399,0.00399189,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,45,9.618,0.006,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,51,29.662,0.018504055,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,52,22.416,0.01398378,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,56,16.825,0.010495945,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,58,24.032,0.01499189,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,59,4.027,0.002512165,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,66,6.386,0.00398378,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,68,4.027,0.002512165,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,73,10.4,0.006487835,Table 1
49OHG,"Herrero et al., 2005","Epidemiologic Profile of Type-Specific Human
Papillomavirus Infection and Cervical Neoplasia
in Guanacaste, Costa Rica",prospective ,1994,Americas,Central America,Costa Rica,Guancaste,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16, 18, 26,  31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68, 73, 82",MY09/11,1603,456,195,82,8.015,0.005,Table 1
51OHG,"Hooi et al., 2018","Human papillomavirus (HPV) prevalence and
associated risk factors in women from
CuracËao",cross-sectional ,NA,Americas,Caribbean,Curaçao,NA,Both,Predominantly normal ,Conventional ,general population,"overall, HR-HPV, 16/18",GP5+/GP6+,305,52,27,16/18,5.978,0.0196,"Table 2 for prevalence by age group, overall, and all subtypes; Figure 1 for HRHPV and HPV 16/18 (with Plot digitizer)"
48HG,"Choi et al., 2015","The Clinical Performance of Primary HPV Screening,
Primary HPV Screening Plus Cytology Cotesting, and
Cytology Alone at a Tertiary Care Hospital",cross-sectional ,2012,Asia,Eastern Asia,South Korea,Ansan,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16/18",multiple,289,NA,66,16/18,16,0.055363322,Table 4 for prevalence by age group and HR-HPV and HPV16/18
52OHG,"Jiang et al., 2011","Type-specific prevalence of Human Papillomavirus infection among women in the Northwest Territories, Canada",cross-sectional ,2009,Americas,North America,Canada,Northwest Territories,Both ,Predominantly normal ,LBC,screening ,"overall, HR-HPV, 16/18",PGMY09/11 and GP5+/GP6+,913,135,94,16/18,13.81,0.015125958,table 2
56OHGP,"Kjaer et al., 2008","Population-based prevalence, type- and age-specific distribution of HPV in
women before introduction of an HPV-vaccination program in Denmark",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16/18",HC2,NA,NA,NA,16/18,NA,0.01355,"N is not provided for the age groups but overall prevalence is provided  by age group (50-54, 55-59, 60-64, 65+) from which a crude overall prevalence is calculated by added up all the prevalence rates, divide the sum by the total number of groups (N) to calculate the crude overall prevalence."
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,16,10,0.005763689,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,18,1,0.000576369,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,31,4,0.002305476,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,33,2,0.001152738,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,35,0,0,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,39,4,0.002305476,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,45,4,0.002305476,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,51,4,0.002305476,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,52,3,0.001729107,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,56,1,0.000576369,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,58,2,0.001152738,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,59,2,0.001152738,"Results from Table 1  by age group *55-64, 65+) and genotype"
57OHG,"Klug et al., 2007",Prevalence of Human Papillomavirus Types in Women Screened by Cytology in Germany,cross-sectional ,2000,Europe,Western Europe,Germany,Southern and Northern Germany,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66",PGMY09/11 ,1735,44,33,66,2,0.001152738,"Results from Table 1  by age group *55-64, 65+) and genotype"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,16,69.68,0.012186079,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,18,27.52,0.004812872,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,31,50.77,0.008878979,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,33,23.25,0.004066107,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,35,12.5,0.002186079,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,39,30.03,0.005251836,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,45,34.68,0.006065058,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,51,50.394,0.008813221,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening ,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,52,66.85,0.011691151,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,53,31.1,0.005438965,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,56,43.6,0.007625044,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,58,18.22,0.003186429,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,59,16.08,0.002812172,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,66,45.74,0.0079993,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
50HG,"Kjaer et al., 2013","Carcinogenic HPV prevalence and age-specific type distribution
in 40,382 women with normal cervical cytology, ASCUS/LSIL,
HSIL, or cervical cancer: what is the potential for prevention?",cross-sectional ,2005,Europe,Northern Europe,Denmark,Copenhagen,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68",HC2,5718,NA,405,68,38.95,0.006811822,"Results from table 1 by % prevalence for genotype  x N of age group (55-64, 65 +), and then summed"
58OHG,"Kobetz et al., 2012","Burden of Human Papillomavirus among Haitian Immigrants in Miami, Florida: Community-Based Participatory Research in Action",cross-sectional ,2008,Americas,North America,USA,"Little Haiti, Miami",Both ,Predominantly normal ,LBC,general population,"overall, HR-HPV, 16/18",PCR L1 or E1,54,10,5,16/18,0,0,"Figure 2 for age specific prevalence of HPV by overall point prevalence, HR and types 16/18"
52HG,"Laowahutanont et al., 2014","Prevalence of High Risk Human Papillomavirus Infection with Different Cervical Cytological Features among Women
Undergoing Health Examination at the National Cancer Institute, Thailand",cross-sectional ,2011,Asia ,Southeastern asia,Thailand,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18 ",other PCR,33,NA,4,16,1,0.03030303,"Table 1 for HPV prevalence by age group 60 +  Hr-HPV+, type 16 and type 18"
52HG,"Laowahutanont et al., 2014","Prevalence of High Risk Human Papillomavirus Infection with Different Cervical Cytological Features among Women
Undergoing Health Examination at the National Cancer Institute, Thailand",cross-sectional ,2011,Asia ,Southeastern asia,Thailand,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18 ",other PCR,33,NA,4,18,1,0.03030303,"Table 1 for HPV prevalence by age group 60 +  Hr-HPV+, type 16 and type 18"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,16,4995,0.264145955,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,18,1340.6,0.070893707,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,31,615.6,0.032554204,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,33,469.38,0.024821787,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,35,695.75,0.036792702,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,39,242.7,0.012834479,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,45,434.4,0.022971973,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,51,758.2,0.040095188,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,52,5054.5,0.267292438,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,56,1133,0.059915389,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,58,2097,0.110893707,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,59,175.2,0.009264939,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
59OHG,"Lee et al., 2012","Prevalence and Distribution of Human Papillomavirus Infection
in Korean Women as Determined by Restriction Fragment Mass
Polymorphism Assay",cross-sectional ,2011,Asia,Eastern Asia,South Korea,Seoul,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",PGMY09/11,18910,6199,2836,68,896.3,0.047398202,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50-59, 60-69, 70-79), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,16,52.4,0.003573621,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,18,14.9,0.001016163,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,31,36.2,0.002468799,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,33,18.02,0.001228944,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,35,18.02,0.001228944,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,39,18.02,0.001228944,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,45,24.03,0.001638819,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,51,18.02,0.001228944,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,52,30.2,0.002059606,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,56,18.33,0.001250085,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,58,24.1,0.001643593,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,59,9.22,0.000628794,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
60OHG,"Leinonen et al., 2013","Type- and age-specific distribution of human
papillomavirus in women attending cervical
cancer screening in Finland",cross-sectional ,2005,Europe,Northern Europe,Finland,NA,Both,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68",HC2,14663,713,321,68,30.88,0.002105981,"Figure 2 for distribution of HR-HPV genotypes by age group, summed prevalence rate for each genotype and age group. Results from table 1 by % prevalence for genotype  x N of age group (50, 55, 60, 65), and then summed"
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,16,43.3,0.156884058,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,18,13.6,0.049275362,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,31,13.6,0.049275362,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,33,8.03,0.029094203,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,35,8.03,0.029094203,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,39,24.28,0.087971014,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,45,2.59,0.009384058,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,51,16.25,0.058876812,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,52,56.8,0.205797101,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,56,29.7,0.107608696,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,58,21.6,0.07826087,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,59,16.25,0.058876812,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,66,5.6,0.020289855,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,68,13.6,0.049275362,Figure 3 distribution fo HPV genotypes by age
53HG,"Li et al., 2020","Prevalence and Genotype Distribution of High-Risk Human Papillomavirus
among Chinese Women in Sichuan Province",retrospective,2017,Asia,Eastern Asia,China,Sichuan,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, 82",other PCR,276,NA,80,82,2.6,0.00942029,Figure 3 distribution fo HPV genotypes by age
54HG,"Li et al., 2006","Human papillomavirus infection in Shenyang City, People’s Republic of China: a population-based study",cross-sectional ,2005,Asia,Eastern Asia,China,Shenyang,Both,Predominantly normal ,LBC,general population," HR-HPV, 16/18",GP5+/GP6+,93,NA,5,16/18,0.957,0.010290323,Figure 1 distribution of HPV genotypes by age
66OHGP,"Marais et al., 2008",Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women,case control ,2006,Africa,Southern Africa,South Africa,Cape Town,Both,Predominantly normal ,conventional,controls,"overall, HR-HPV, 16",other PCR,NA,NA,NA,16,NA,0.0233,"% prevalence of HPV 16 by age group reported in Figure 1,  however the N for each age group was not provided"
67OHG,"Moore et al., 2009","Prevalence and type distribution of human papillomavirus
in 5,000 British Columbia women—implications for vaccination",cross-sectional ,2004,Americas,North America,Canada,British Columbia,Both,Predominantly normal ,LBC,screening ,"overall, HR-HPV, 16,18, 16/18",GP5+/GP6+,1138,132,116,16/18,108,0.094923692, study sample by age  in table 4; and plot digitizer on figure 2a for HPV 16/18 by age group 
67OHG,"Moore et al., 2009","Prevalence and type distribution of human papillomavirus
in 5,000 British Columbia women—implications for vaccination",cross-sectional ,2004,Americas,North America,Canada,British Columbia,Both,Predominantly normal ,LBC,screening ,"overall, HR-HPV, 16,18, 16/18",GP5+/GP6+,1138,132,116,16,102.4,0.090001723, study sample by age  in table 4; and plot digitizer on figure 2b for HPV 16  by age group 
67OHG,"Moore et al., 2009","Prevalence and type distribution of human papillomavirus
in 5,000 British Columbia women—implications for vaccination",cross-sectional ,2004,Americas,North America,Canada,British Columbia,Both,Predominantly normal ,LBC,screening ,"overall, HR-HPV, 16,18, 16/18",GP5+/GP6+,1138,132,116,18,30.7,0.026982938, study sample by age  in table 4; and plot digitizer on figure 2b for HPV 18  by age group 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,16,2.4,0.032876712,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,18,1.02,0.013972603,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,31,0.584,0.008,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,33,0.876,0.012,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,35,0.657,0.009,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,39,0.511,0.007,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,45,0.876,0.012,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,51,0.584,0.008,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,52,0.584,0.008,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,56,0.146,0.002,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,58,0.584,0.008,Based on Table 1 
68OHG,"Mudderis et al., 2019",HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey,retrospective,2015,Asia,Western Asia,Turkiye,NA,Both ,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59",LA,73,13,9,59,0.073,0.001,Based on Table 1 
63HGP,"Ucakar et al., 2012","Pre-vaccination prevalence and distribution of high-risk human papillomavirus
(HPV) types in Slovenian women: A cervical cancer screening based study",cross-sectional ,2010,Europe ,Southern Europe,Slovenia,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",LA,NA,NA,NA,16,NA,0.00313,"% prevalence of type 16, 18 by age group reported in Figure 1,  however the N for each age group was not provided. Plot digitizer used"
63HGP,"Ucakar et al., 2012","Pre-vaccination prevalence and distribution of high-risk human papillomavirus
(HPV) types in Slovenian women: A cervical cancer screening based study",cross-sectional ,2010,Europe ,Southern Europe,Slovenia,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",LA,NA,NA,NA,18,NA,0.00207,"% prevalence of type 16, 18 by age group reported in Figure 1,  however the N for each age group was not provided. Plot digitizer used"
78OG,"Vu et al., 2013",Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign,cross-sectional ,2011,Asia,Southeastern asia,Vietnam,NA,Both,Predominantly normal ,conventional,general population,"overall, 16/18",other PCR,957,NA,82,16/18,56.463,0.059,"Table 1 for N of age groups, Figure 3 for for overall and type 16/18 prevalence by age group"
65HG,"Wright et al., 2012","The ATHENA human papillomavirus study: design, methods, and baseline results",cross-sectional ,2009,Americas,North America,USA,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",cobas,10581,NA,639,16,83,0.007844249,"TABLE 3
HPV prevalence by age group identified using the cobas HPV Test"
65HG,"Wright et al., 2012","The ATHENA human papillomavirus study: design, methods, and baseline results",cross-sectional ,2009,Americas,North America,USA,NA,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",cobas,10581,NA,639,18,44,0.004158397,"TABLE 3
HPV prevalence by age group identified using the cobas HPV Test"
83OHG,"Yip et al., 2010",Prevalence and Genotype Distribution of Cervical Human Papillomavirus Infection in Macao,cross-sectional ,2008,Asia ,Eastern Asia,China ,Macao,Both ,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18",PGMY09/11,400,51,41,16,9.854,0.024635,"Figure 1 for overall and HR-HPV+, 16, 18 type by age group extracted with plotdigitizer"
83OHG,"Yip et al., 2010",Prevalence and Genotype Distribution of Cervical Human Papillomavirus Infection in Macao,cross-sectional ,2008,Asia ,Eastern Asia,China ,Macao,Both ,Predominantly normal ,LBC,screening,"overall, HR-HPV, 16, 18",PGMY09/11,400,51,41,18,2.9998,0.0074995,"Figure 1 for overall and HR-HPV+, 16, 18 type by age group extracted with plotdigitizer"
85OHG,"Zhu et al., 2021","Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018–2019",retrospective,2019,Asia ,Eastern Asia,China ,Huzhou,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 52, 53, 58, 81",cobas,745,175,155,16,26.06,0.034979866,"Figure 2C for type 16, 52, 53, 58, 81, by age group with plotdigitizer"
85OHG,"Zhu et al., 2021","Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018–2019",retrospective,2019,Asia ,Eastern Asia,China ,Huzhou,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 52, 53, 58, 81",cobas,745,175,155,52,36.035,0.048369128,"Figure 2C for type 16, 52, 53, 58, 81, by age group with plotdigitizer"
85OHG,"Zhu et al., 2021","Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018–2019",retrospective,2019,Asia ,Eastern Asia,China ,Huzhou,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 52, 53, 58, 81",cobas,745,175,155,53,17.902,0.02402953,"Figure 2C for type 16, 52, 53, 58, 81, by age group with plotdigitizer"
85OHG,"Zhu et al., 2021","Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018–2019",retrospective,2019,Asia ,Eastern Asia,China ,Huzhou,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 52, 53, 58, 81",cobas,745,175,155,58,24.13,0.032389262,"Figure 2C for type 16, 52, 53, 58, 81, by age group with plotdigitizer"
85OHG,"Zhu et al., 2021","Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018–2019",retrospective,2019,Asia ,Eastern Asia,China ,Huzhou,Both,Predominantly normal ,LBC,clinical setting ,"overall, HR-HPV, 16, 52, 53, 58, 81",cobas,745,175,155,81,22.052,0.0296,"Figure 2C for type 16, 52, 53, 58, 81, by age group with plotdigitizer"
21HG,"Preisler et al., 2013","Prevalence of Human Papillomavirus in 5,072
Consecutive Cervical SurePath Samples Evaluated with
the Roche Cobas HPV Real-Time PCR Assay",cross-sectional ,2011,Europe,Northern Europe,Denmark,Copenhagen,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",multiple,785,NA,77,16,17,0.021656051,"used the cobas results, and data from Fig 1 and Table 1"
21HG,"Preisler et al., 2013","Prevalence of Human Papillomavirus in 5,072
Consecutive Cervical SurePath Samples Evaluated with
the Roche Cobas HPV Real-Time PCR Assay",cross-sectional ,2011,Europe,Northern Europe,Denmark,Copenhagen,Both ,Predominantly normal ,LBC,screening,"HR-HPV, 16, 18",multiple,785,NA,77,18,5,0.006369427,"used the cobas results, and data from Fig 1 and Table 1"
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,16,102,0.159375,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,18,67,0.1046875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,31,50,0.078125,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,33,57,0.0890625,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,35,36,0.05625,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,39,67,0.1046875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,45,38,0.059375,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,51,56,0.0875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,52,147,0.2296875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,56,41,0.0640625,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,58,108,0.16875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,59,22,0.034375,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,66,27,0.0421875,overall type specific from Table S3
23HG,"Du et al., 2021",The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features,cross-sectional ,2018,Asia ,Eastern Asia,China ,NA,Both ,Predominantly normal ,NA,screening,"16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66, 68",multiple,640,NA,NA,68,42,0.065625,overall type specific from Table S3
41HGP,"Gultekin et al., 2018","Initial results of population based cervical cancer screening
program using HPV testing in one million Turkish women",cross-sectional ,2016,Asia,Western Asia,Turkiye,NA,Both,Predominantly normal ,Conventional,screening,"HR-HPV, 16/18",HC2,NA,NA,NA,16/18,NA,0.0009,% prevalence of overall HPV by age group reported in Figure 3 however the N for each age group was not provided
46HGP,"Jiang et al., 2013","The prevalence of human papillomavirus and its
impact on cervical dysplasia in Northern Canada",cross-sectional ,2010,Americas,North America,Canada,Northwest Territories,Both,Predominantly normal ,LBC,screening,"HR-HPV, 16/18",PGMY09/11 and GP5+/GP6+,NA,NA,NA,16/18,NA,0.01594,figure 2 using plot digitizer
26OGP,"Borena et al., 2016","Pre-vaccine era cervical human
papillomavirus infection among screening
population of women in west Austria",cross-sectional ,2015,Europe,Western Europe,Austria,Tyrol,Both ,Predominantly normal ,LBC,clinical setting ,"Overall, 16, 18",other PCR,NA,NA,NA,16,NA,0.0325," Figure 2 gives the prevalence by age group, however it is difficult to determine the # of infected subjects because there is no breakdown of the # of subjects by age group. % prevlence on the Y axis?"
26OGP,"Borena et al., 2016","Pre-vaccine era cervical human
papillomavirus infection among screening
population of women in west Austria",cross-sectional ,2015,Europe,Western Europe,Austria,Tyrol,Both ,Predominantly normal ,LBC,clinical setting ,"Overall, 16, 18",other PCR,NA,NA,NA,18,NA,0.008," Figure 2 gives the prevalence by age group, however it is difficult to determine the # of infected subjects because there is no breakdown of the # of subjects by age group. % prevlence on the Y axis?"
42HGP,"Hatzipanagiotou et al., 2018","Human papillomaviruses in Western Africa: prevalences and risk
factors in Burkina Faso",cross-sectional ,2014,Africa,Western Africa,Burkina Faso,Ouagadougou,Both,Predominantly normal ,VIA,screening,"HR-HPV, 16/18",GP5+/GP6+,NA,NA,NA,16/18,NA,0.0727,"Figure 1, data for 51+ extracted with plot digitizer"
70HGP,"Lu et al., 2015","Distribution of High-Risk Human Papillomavirus Genotypes in HPV-Infected Women in Beijing, China",retrospective,2013,Asia,Eastern Asia,China,Beijing,Both,Predominantly normal ,NA,clinical setting ,"HR-HPV, 16",GP5+/GP6+,NA,NA,155,16,7,0.0705,Data from Table 1